v3.25.2
SUPPLEMENTAL BALANCE SHEET INFORMATION
 12 Months Ended
Jun. 30, 2025
Supplemental Balance Sheet Information [Abstract]  
SUPPLEMENTAL BALANCE SHEET INFORMATION
(8) SUPPLEMENTAL BALANCE SHEET INFORMATION
Accounts Receivable, Net
Trade accounts receivable consisted of amounts due for services and products from hospital and healthcare members, distributors, and other customers.
Accounts receivable, net consisted of the following (in thousands):
June 30,
20252024
Trade accounts receivable$104,810 $101,709 
Other621 648 
Total accounts receivable105,431 102,357 
Allowance for credit losses(6,339)(1,392)
Accounts receivable, net$99,092 $100,965 
Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
June 30,
Useful life20252024
Capitalized software
2-5 years
$928,036 $856,730 
Computer hardware
3-5 years
67,204 64,761 
Furniture and other equipment5 years7,062 7,061 
Leasehold improvementsLesser of estimated useful life or term of lease19,222 19,222 
Total property and equipment1,021,524 947,774 
Accumulated depreciation and amortization(820,043)(742,063)
Property and equipment, net$201,481 $205,711 
Depreciation and amortization expense related to property and equipment was $79.4 million, $81.7 million, and $85.7 million for the years ended June 30, 2025, 2024, and 2023, respectively. Unamortized capitalized software costs were $180.6 million and $178.6 million at June 30, 2025 and 2024, respectively.
During the years ended June 30, 2025 and June 30, 2024, the Company incurred impairments of long-lived assets of $2.8 million and $9.8 million, respectively, related to the Contigo Health reporting unit as the carrying value of the assets was not recoverable. The Company did not incur a material loss on disposal or impairment of long-lived assets during the year ended June 30, 2023.
Other Long-Term Assets
Other long-term assets consisted of the following (in thousands):
June 30,
20252024
Contract assets, less current portion$58,527 $59,025 
Capitalized contract costs25,767 25,506 
Other (a)
11,211 14,218 
Total other long-term assets$95,505 $98,749 
_________________________________
(a)Includes deferred loan costs, net of $1.9 million and $2.7 million as of June 30, 2025 and 2024, respectively.
Contract costs include capitalized sales commissions and implementation costs. See Note 7 - Contract Balances for further information.
The Company recorded amortization expense on deferred loan costs of $0.8 million, $0.8 million, and $0.7 million the years ended June 30, 2025, 2024, and 2023, respectively. Amortization expense on deferred loan costs was recognized based on the straight-line method, which approximates the effective interest method, and was included in interest expense, net in the Consolidated Statements of Income and Comprehensive Income.
Other Long-Term Liabilities
Other long-term liabilities consisted of the following (in thousands):
June 30,
20252024
Reserve for uncertain tax positions$19,202 $23,225 
Earn-out liability, less current portion7,706 — 
Other1,153 4,415 
Total other long-term liabilities$28,061 $27,640 
Earn-out liabilities were established in connection with the IllumiCare acquisition. See Note 6 - Fair Value Measurements for further information.